Replies to post #7615 on Nutra Pharma Corp (NPHC)

[PashkaVl]

Lol... yeah Vicodin and other prescribed pain relievers are a small niche market. Don't make me laugh.

[slbrown]

Once again here are the real facts!

You stated this:

Nyloxin and Cobroxin have no hope to be successes because NPHC has no money or expertise to performa real marketing program.

Here is the real facts:
Henry Schein and Nutritional Alliance have been hired to handle the Nyloxin roll out here in the US and abroad. This means that Nyloxin will just beginning to be promoted and distributed throughout the US and overseas, so your statement of no money or expertise is false! Plus the CEO has stated the following: "We scaled up venom production, scaled up Nyloxin manufacturing and continued with the international regulatory paperwork to distribute Nyloxin in more than 20 countries. Lastly, we have now secured up to $10 million in funds that we may draw as necessary to insure an effective roll-out of Nyloxin. It is the Company's wish to utilize as little of this financing as possible - as we grow Nyloxin sales and attempt to fund the Company through revenue generation"

You stated this:

Nyloxin is a different market and Henry Schein will not spend money on advertizing. The market for Doctors is much smaller than the market for large retail chains. It is tiny and an uphill battle.

The fact is this:
The market for Doctors is not tiny! It is HUGE! I am talking from experience, as I have worked in the pharmaceutical industry for 20 years! The potential for success is much greater with Nyloxin and they have a world recognized distributor (Henry Schein) that is well equipped to handle Nyloxin! Tell the likes of Pfizer, J&J, Lily, etc. etc. that the market for Doctors for an alternative pain reliever is tiny and they will laugh you all the way out the front door! The fact is that many of the top pharma companies are scrambling to find alternative pain relievers due to the acetaminophen controversy!

You stated this:

In short, these products and this company are failures.

Fact is:
You do not know or could know at this point, especially because Nyloxin is just being rolled out and Cobroxin was subjected to less than anticipated promotions from their distributor Xenacare. There is much more to come in regards to these products and it is definitely premature to make any assumptions based on pure speculation at this point. Yes there has been some outages and mistakes made, but those are being addressed and we need to be patient as they continue to push forward with new marketing plans for the future.

FYI - here are a few more misleading comments that need addressing:
Nyloxin was not intended to cannibalize Cobroxin and that again was pure speculation without any factual basis.

Henry Schein was never expected to advertise Nyloxin and that is not what they were hired for. They were hired to distribute and promote, which is mostly done by the reps calling on the physicians and not by advertising. Overseas Nyloxin will be promoted to retail outlets for over the counter sales.

Due to less than expected promotional activity by the distributor does not mean that Cobroxin was a failure. It would be more like XCHO did not perform as expected. Despite that, XCHO will continue to promote the product as per the contract NPHC has set forth and until there is change announced, we can not label it as a failure based purely off speculation at this point.

Misc. Info for investors: The new IR person for NPHC is: Nina Goldstein - (tele)877-895-5647